GFAP and spinocerebellar ataxia 7: Nonetheless, we present the largest cohort of symptomatic SCA7 in biomarker studies reported to date, and further support NfL, and potentially GFAP, as biomarkers to inform on disease status, progression, and clinical trial efficacy in SCA7.